Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2Endocrine 1

Conditions

Breast Neoplasms 24Neoplasm Metastasis 5Triple Negative Breast Neoplasms 2Recurrence 2Ovarian Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Lymphatic Abnormalities 2Lymphangioma, Cystic 2Lymphangioma 2Hyperglycemia 2Hereditary Sensory and Autonomic Neuropathies 2Vascular Malformations 1Squamous Cell Carcinoma of Head and Neck 1Skin Diseases, Vascular 1Melanoma 1Hormone Receptor Positive Breast Carcinoma 1Head and Neck Squamous Cell Cancer 1Head and Neck Neoplasms 1HER2-positive Metastatic Breast Cancer 1Genetic Diseases, Inborn 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Arteriovenous Malformations 1Advanced HER2+Breast Cancer 1Advanced Breast Cancer 1

Interventions

Alpelisib 2exemestane 1Vildagliptin 1Tamoxifen 1Standard of Care 1Metformin 1Letrozole 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hyperglycemia × Alpelisib × 1 year × Clear all
NCT06083038 2026-05-06

Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib

HealthPartners Institute

Completed
8 enrolled
Breast

Breast Neoplasms, Hyperglycemia

NCT04300790 2025-07-29

METALLICA

MedSIR

Phase 2 Completed
69 enrolled
BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡